Drug recall · May 1, 2024
Abilify recall
Why: Cross Contamination with Other Products
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13
- Lots / codes
Lot # AKS00623A, Exp 01/31/2026; AKS00322A, Exp 02/28/2025
- Quantity
- 108,192/30 count bottles or 7 count blister packs
- Company
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd., Tokushima, N/A
- Distribution
- USA nationwide.
- Initiated
- April 9, 2024 · Voluntary: Firm initiated
- Classified
- April 23, 2024
- Reported
- May 1, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Abilify
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.